Literature DB >> 17292995

A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.

Ivelina Gueorguieva1, Kayode Ogungbenro, Gordon Graham, Sophie Glatt, Leon Aarons.   

Abstract

The design of pharmacokinetic and pharmacodynamic experiments concerns a number of issues, among which are the number of observations and the times when they are taken. Often a model is used to describe these data and the pharmacokinetic-pharmacodynamic behavior of a drug. Knowledge of the data analysis model at the design stage is beneficial for collecting patient data for parameter estimation. A number of criteria for model-oriented experiments, which maximize the information content of the data, are available. In this paper we present a program, Popdes, to investigate the D-optimal design of individual and population multivariate response models, such as pharmacokinetic-pharmacodynamic, physiologically based pharmacokinetic, and parent drug and metabolites models. A pre-clinical and clinical pharmacokinetic-pharmacodynamic model describing the concentration-time profile and effect of an oncology compound in development is used for illustration.

Entities:  

Mesh:

Year:  2007        PMID: 17292995     DOI: 10.1016/j.cmpb.2007.01.004

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  21 in total

1.  Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.

Authors:  Kerenaftali Klein; Ivelina Gueorguieva; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

2.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

3.  Simultaneous optimal experimental design on dose and sample times.

Authors:  Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-25       Impact factor: 2.745

4.  Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Authors:  Marylore Chenel; François Bouzom; Leon Aarons; Kayode Ogungbenro
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-07       Impact factor: 2.745

5.  Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.

Authors:  Holger Dette; Andrey Pepelyshev; Weng Kee Wong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-22       Impact factor: 2.745

6.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

7.  Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.

Authors:  Marion Bouillon-Pichault; Vincent Jullien; Caroline Bazzoli; Gérard Pons; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-04       Impact factor: 2.745

8.  Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.

Authors:  Giulia Lestini; Cyrielle Dumont; France Mentré
Journal:  Pharm Res       Date:  2015-06-30       Impact factor: 4.200

9.  Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.

Authors:  Cyrielle Dumont; France Mentré; Clare Gaynor; Karl Brendel; Charlotte Gesson; Marylore Chenel
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

10.  Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.

Authors:  Kayode Ogungbenro; Sharon Hulme; Nancy Rothwell; Stephen Hopkins; Pippa Tyrrell; James Galea
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.